Brief: Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 Awarded Additional Funding From U.S. Air Force Academy
25/10/2023 13:29
Oct 25 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS’ BIODEFENSE VACCINE CANDIDATE ATI-1701
IS
AWARDED ADDITIONAL FUNDING FROM THE U.S. AIR FORCE ACADEMY
* APPILI THERAPEUTICS INC - ADDITIONAL US$6.6 MILLION
FUNDING
COMMITMENT FOR ATI-1701 BRINGS TOTAL PROGRAM FUNDING AWARDED TO
APPROXIMATELY US$14 MILLION
* APPILI THERAPEUTICS- FUNDS ALONG WITH OTHER POTENTIAL
FUNDING
SOURCES, ANTICIPATED TO ADVANCE ATI-1701 PROGRAM TOWARD AN IND
SUBMISSION TO FDA IN 2024
Source text for Eikon: ID:nBw7mwzZ0a
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez